

ARVO 2024

View Abstract

CONTROL ID: 4051826**SUBMISSION ROLE:** Abstract Submission**AUTHORS****AUTHORS (LAST NAME, FIRST NAME):** [Grimes, Daniel](#)¹; Matei, Ioan V.¹; Paraoan, Luminita I.¹**INSTITUTIONS (ALL):** 1. Ocular Molecular Biology and Mechanisms of Disease Group, Faculty of Arts and Sciences, Edge Hill University, Ormskirk, United Kingdom.**Commercial Relationships Disclosure:** Daniel Grimes: Commercial Relationship: Code N (No Commercial Relationship) | Ioan Matei: Commercial Relationship: Code N (No Commercial Relationship) | Luminita Paraoan: Commercial Relationship: Code N (No Commercial Relationship)**Study Group:** (none)**ABSTRACT****TITLE:** Modulation of inflammatory-related signalling by PERP-mediated apoptosis in uveal melanoma cells**ABSTRACT BODY:****Purpose:** Downregulation of PERP (p53 apoptosis effector related to PMP22) is a determinant of impaired apoptosis in aggressive monosomy 3 Uveal Melanoma (UM). The functional importance of PERP downregulation in this scenario is further supported by the requirement of chromosome 3-localised p63 for PERP transcription. Given the role of p63-mediated signalling in inflammatory responses, we hypothesised that altered levels of PERP influence the major NFκB inflammatory signalling pathway.**Methods:** The effect of increased PERP expression on NFκB-related proteins was investigated in the human UM cell line Mel202. Changes of specific NFκB proteins and gene expression were assessed in cells transiently transfected with GFP-tagged PERP for 24 hours using Proteome (R&D Systems) and TaqMan (ThermoFisher) NFκB Pathway Arrays. A total of 45 proteins including 4 serine or tyrosine phosphorylation sites and 92 genes, respectively, were analysed. Phosphorylated and non-phosphorylated I Kappa B Alpha (p-IκBα/IκBα) protein expression was determined by immunoblotting.**Results:** Following increased PERP expression, protein levels of the transcription factors cRel, p65, p105/p50 and p100/p52 decreased compared to GFP-only control by 0.63-fold, 0.63-fold, 0.85-fold and 0.73-fold, respectively, 24 hours post-transfection (PT). Decreased protein levels mirrored gene expression changes of cRel, p65 and p105/p50, with the exception of p100/p52 which showed an increase by 4.4-fold. While the increase in PERP level did not lead to changes in non-phosphorylated IκBα protein expression at 24 or 48 hours PT, p-IκBα level showed a significant decrease by 0.61-fold (+/-0.042) followed by a significant increase by 1.4-fold (+/-0.019) after 48 hours (One-Way ANOVA +/-SEM, p<0.05, n=3).**Conclusions:** The results support the hypothesis that increased PERP expression in UM cells affect gene/protein expression related to NFκB signalling pathway. The initial response is characterised by a decrease in transcription factors involved in the translocation and activation of NFκB, corroborated by a decrease in p-IκBα, therefore retaining NFκB in an inactive state, which is conceivably in line with the non-inflammatory characteristics of apoptosis. The subsequent increase of p-IκBα level suggests differences between an early and late response in relation to induction of apoptosis by PERP.

(No Image Selected)

DETAILS**PRESENTATION TYPE - PLEASE NOTE, IF YOU CHANGE YOUR PRESENTATION TYPE AFTER APPLYING FOR AN AWARD (BELOW), YOU MUST GO BACK AND RESELECT THE APPLY BUTTON.:**

Poster Only : Travel Award Applicant

CURRENT REVIEWING CODE: 1500 Biochemistry/Molecular Biology: Other - BI**CURRENT SECTION:** Biochemistry/Molecular Biology**Clinical Trial Registration (Abstract):** No**Other Registry Site (Abstract):** (none)**Registration Number (Abstract):** (none)

Date Trial was Registered (MM/DD/YYYY) (Abstract): (none)

Date Trial Began (MM/DD/YYYY) (Abstract): (none)

Grant Support (Abstract): Yes

Support Detail (Abstract): The Humane Research Trust UK

TRAVEL GRANTS and AWARDS APPLICATIONS

AWARDS: ARVO and ARVO Foundation Travel Grants|Association for Research in Vision and Ophthalmology - International (ARVO-I)|ARVO Foundation (Intl)|Fight for Sight/Vision Foundation|Joanne G. Angle|Michael A. Steinmetz, PhD Memorial Travel Grant



© Clarivate Analytics | © ScholarOne, Inc., 2024. All Rights Reserved.

ScholarOne Abstracts and ScholarOne are registered trademarks of ScholarOne, Inc.
ScholarOne Abstracts Patents #7,257,767 and #7,263,655.

[@Clarivate](#) | [System Requirements](#) | [Privacy Statement](#) | [Terms of Use](#)

Product version number 4.17.4 (Build 225). Build date Tue Jan 30 08:58:43 EST 2024. Server ip-10-236-27-21